Additional file 1: Figure S1. of A novel 11C-labeled thymidine analog, [11C]AZT, for tumor imaging by positron emission tomography

PET images of C6 and HeLa tumor-bearing mice between 30 and 60 min after injection of 50 MBq of [11C]AZT (A) and [11C]d4T (B). Arrows and arrowheads indicate the C6 and HeLa tumors, respectively. Figure S2 [11C]AZT and [18F]FDG uptake in aseptic inflammation model mice. Representative coronal PET images for [11C]AZT (A) and [18F]FDG (B) between 60–80 min after injection. Yellow dot circles indicated turpentine oil-induced inflammatory tissue. Biodistribution of [11C]AZT (C) and [18F]FDG (D) in turpentine oil-treated (black bar) and untreated (white bar) posterior thigh muscles. Data are means ± SD (n = 5, ***P < 0.001). Histological analysis by hematoxylin and eosin staining of turpentine oil-untreated (E) and treated (F) muscles. Scale bar = 1 mm. Figure S3 The accumulation levels in bone and tumor of [11C]d4T, [11C]AZT, and [11C]4DST. Thigh bones and tumors were collected after 80 min PET probe injection. Radioactivities in these tissues were measured by γ-well counter. The graph in (A) shows the %ID/g for tumor tissue and bone. Data are presented as means ± SD (n = 4 to 6). **P < 0.01 vs. [11C]AZT and [11C]d4T injected mouse. †P < 0.01 vs. [11C]d4T injected mouse. The graph in (C) shows the ratio of tumor-to-bone uptake of the labeled probes. *P < 0.05 vs. [11C]4DST injected mice. **P < 0.01 vs. [11C]d4T injected mice